AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9612600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 131I-polyclonal antiferritin (added to either regimen)
Number of subjects: 0
Study 7927192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD), 120 mg po
Number of subjects: 5
Study 7927192 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 2 tablets po
Number of subjects: 5
Study 7927192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone succinate infusion (100 mg bolus followed by 250 mg infusion)
Number of subjects: 5
Study 7927192 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (2 ml bolus followed by 250 ml infusion)
Number of subjects: 5
Study 2521027 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (5 mg)
Number of subjects: 20
Study 2521027 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 mL of nicardipine solvent)
Number of subjects: 20
Study 30705602 — intervention group
Group type: EXPERIMENTAL
Intervention: S-8117 (controlled-release oxycodone)
Number of subjects: 189
Study 30705602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 28951845 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy (twice per week for 2 weeks)
Number of subjects: 50
Study 28951845 — intervention group
Group type: COMPARATOR
Intervention: Manual acupuncture (thrice per week for 2 weeks)
Number of subjects: 50
Study 28951845 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy
Number of subjects: 50
Study 28951845 — intervention group
Group type: COMPARATOR
Intervention: Manual acupuncture
Number of subjects: 50
Study 28951845 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy and Manual acupuncture
Number of subjects: 50
Study 25207592 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity
Number of subjects: 60
Study 25207592 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Number of subjects: 60
Study 25207592 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade III breast cancer
Number of subjects: 60
Study 25207592 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional occupation
Number of subjects: 60
Study 25207592 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to nutritional guidelines
Number of subjects: 60
Study 25207592 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive adiposity
Number of subjects: 60
Study 23801867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track surgery (FTS)
Number of subjects: 119
Study 21795442 — intervention group
Group type: EXPERIMENTAL
Intervention: High Carbohydrates (HC) breakfast
Number of subjects: 16
Study 21795442 — intervention group
Group type: EXPERIMENTAL
Intervention: High Fat (HF) breakfast
Number of subjects: 16
Study 21795442 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Carbohydrates (LC) breakfast
Number of subjects: 16
Study 21795442 — intervention group
Group type: COMPARATOR
Intervention: Low Fat (LF) breakfast
Number of subjects: 16
Study 20462102 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical supervision
Number of subjects: 0
Study 20462102 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18198636 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax quinquefolius saponin (PQS) given orally for 4 weeks
Number of subjects: 84
Study 18198636 — intervention group
Group type: COMPARATOR
Intervention: Routine Western medicine treatment
Number of subjects: 84
Study 15548587 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobromine
Number of subjects: 0
Study 15548587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12392870 — intervention group
Group type: EXPERIMENTAL
Intervention: Second BCG vaccination
Number of subjects: 242401
Study 12392870 — intervention group
Group type: COMPARATOR
Intervention: Control group (no second BCG vaccination)
Number of subjects: 242401
Study 9972550 — intervention group
Group type: EXPERIMENTAL
Intervention: Persuasive communication from a stigmatized source (Black in Experiment 1; homosexual in Experiment 2)
Number of subjects: 0
Study 9972550 — intervention group
Group type: COMPARATOR
Intervention: Persuasive communication from a nonstigmatized source (White in Experiment 1; heterosexual in Experiment 2)
Number of subjects: 0
Study 7552649 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-time, intensive 3-week multidisciplinary program, including active physical and ergonomic training and psychological pain management, followed by 1 day weekly for the subsequent 3 weeks
Number of subjects: 132
Study 7552649 — intervention group
Group type: COMPARATOR
Intervention: Active physical training, twice a week for 6 weeks, for a total of 24h
Number of subjects: 132
Study 7552649 — intervention group
Group type: COMPARATOR
Intervention: Psychological pain management combined with active physical training, twice a week for 6 weeks, also for a total of 24h
Number of subjects: 132
Study 2197001 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlimited clear fluids up to three hours before surgery
Number of subjects: 121
Study 2197001 — intervention group
Group type: COMPARATOR
Intervention: Prolonged fast (mean fast 14 hr)
Number of subjects: 121
Study 6975197 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25‐dihydroxycholecalciferol [1,25‐(OH)2D3] at 0.25 microgram/day for 4-12 months
Number of subjects: 10
Study 6975197 — intervention group
Group type: EXPERIMENTAL
Intervention: 24,25‐dihydroxycholecalciferol [24,25‐(OH)2D3] at 2 microgram/day for 4-12 months
Number of subjects: 10
Study 30701661 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of Levels (MOL) therapy
Number of subjects: 12
Study 28002685 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-flow restriction (BFR) applied via pressure cuff inflated to 220 mm Hg
Number of subjects: 6
Study 28002685 — intervention group
Group type: COMPARATOR
Intervention: Control (CNTRL) without blood-flow restriction
Number of subjects: 6
Study 24705947 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg
Number of subjects: 0
Study 24705947 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Number of subjects: 0
Study 24705947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24244918 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 (patients without addiction)
Number of subjects: 160
Study 24244918 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 (patients with opium addiction)
Number of subjects: 160
Study 24244918 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1 (patients without addiction)
Number of subjects: 160
Study 24244918 — intervention group
Group type: COMPARATOR
Intervention: Placebo 2 (patients with opium addiction)
Number of subjects: 160
Study 20634639 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 6 and 12 months
Number of subjects: 30
Study 20634639 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (no GH treatment)
Number of subjects: 30
Study 19745176 — intervention group
Group type: EXPERIMENTAL
Intervention: Repinotan (intravenous infusion for 72 hours)
Number of subjects: 681
Study 19745176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous infusion for 72 hours)
Number of subjects: 681
Study 17685990 — intervention group
Group type: EXPERIMENTAL
Intervention: Soup kitchen
Number of subjects: 230
Study 17685990 — intervention group
Group type: EXPERIMENTAL
Intervention: Welfare office
Number of subjects: 230
Study 17685990 — intervention group
Group type: EXPERIMENTAL
Intervention: Detoxification centre
Number of subjects: 230
Study 17685990 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeless outreach team
Number of subjects: 230
Study 17685990 — intervention group
Group type: EXPERIMENTAL
Intervention: Family member
Number of subjects: 230
Study 17685990 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency room
Number of subjects: 230
Study 17685990 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare site (medical condition)
Number of subjects: 230
Study 17685990 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare site (mental health condition)
Number of subjects: 230
Study 17685990 — intervention group
Group type: EXPERIMENTAL
Intervention: Social service agency (medical condition)
Number of subjects: 230
Study 17685990 — intervention group
Group type: EXPERIMENTAL
Intervention: Social service agency (mental health condition)
Number of subjects: 230
Study 17685990 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare site (alcohol treatment need)
Number of subjects: 230
Study 17685990 — intervention group
Group type: EXPERIMENTAL
Intervention: Family or friends (alcohol abuse/dependence)
Number of subjects: 230
Study 15563363 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary service model delivering medication review including GP education, patient home visits, pharmacist medication reviews, primary healthcare team conferences, GP implementation of action plans, and follow-up surgery visits.
Number of subjects: 400
Study 15563363 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary service model delivering medication review
Number of subjects: 400
Study 11677934 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative stomach resection
Number of subjects: 285
Study 11677934 — intervention group
Group type: COMPARATOR
Intervention: Nonresective procedure
Number of subjects: 285
Study 11677934 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative resection
Number of subjects: 285
Study 9131883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 46
Study 9131883 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided mastery therapy
Number of subjects: 46
Study 8201166 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day-old hydrogel lenses
Number of subjects: 18
Study 8201166 — intervention group
Group type: COMPARATOR
Intervention: 2-weeks-old hydrogel lenses
Number of subjects: 18
Study 2979271 — intervention group
Group type: EXPERIMENTAL
Intervention: Kreon (3.6 g/day)
Number of subjects: 15
Study 2979271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30348188 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based home health education intervention administered by female community health volunteers (FCHVs) for 12 months
Number of subjects: 224
Study 30348188 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group managing glycemic condition as usual for 12 months
Number of subjects: 224
Study 26748079 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-duration, high-intensity interval training (15.0 ± 3.5 min, 5 days/week for 12 weeks)
Number of subjects: 18
Study 26748079 — intervention group
Group type: COMPARATOR
Intervention: Traditional exercise (walking for 40.0 ± 5.0 min at 65% of age-predicted maximum heart rate, 5 days/week for 12 weeks)
Number of subjects: 18
Study 25192156 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-sintered surface implants
Number of subjects: 60
Study 25192156 — intervention group
Group type: COMPARATOR
Intervention: Acid-etched surface implants
Number of subjects: 60
Study 22910159 — intervention group
Group type: COMPARATOR
Intervention: Teaching by faculty members
Number of subjects: 28
Study 22910159 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching by senior residents
Number of subjects: 28
Study 20060830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (3 microg/kg, intravenous infusion, twice daily for 10 days)
Number of subjects: 21
Study 20060830 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline, intravenous infusion, twice daily for 10 days)
Number of subjects: 21
Study 18061206 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0
Study 18061206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15862051 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring Code intervention explained by clinical instructors and reminders provided weekly.
Number of subjects: 480
Study 15862051 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Caring Code intervention).
Number of subjects: 480
Study 12503902 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 106
Study 12503902 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 106
Study 9792381 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV) regimen
Number of subjects: 0
Study 7705677 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and sizofiran
Number of subjects: 312
Study 7705677 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and sizofiran with 5-fluorouracil
Number of subjects: 312
Study 7705677 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 312
Study 7705677 — intervention group
Group type: EXPERIMENTAL
Intervention: Sizofiran
Number of subjects: 312
Study 2677271 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized reminder system for physicians
Number of subjects: 39
Study 2677271 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient questionnaire and educational hand-out on preventive care
Number of subjects: 39
Study 2677271 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions used together
Number of subjects: 39
Study 2677271 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 39
Study 491473 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol ophthalmic solution
Number of subjects: 50
Study 491473 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 50
Study 30913165 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored pain coping skills training (CST) program, 11 telephone-based sessions over 3 months
Number of subjects: 248
Study 30913165 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored pain coping skills training (CST) program
Number of subjects: 248
Study 30913165 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 248
Study 27604374 — intervention group
Group type: EXPERIMENTAL
Intervention: FC-assisted TUR with 5-ALA
Number of subjects: 525
Study 27604374 — intervention group
Group type: EXPERIMENTAL
Intervention: Single instillation of doxorubicin
Number of subjects: 525
Study 27604374 — intervention group
Group type: COMPARATOR
Intervention: WL-TUR only
Number of subjects: 525
Study 27604374 — intervention group
Group type: COMPARATOR
Intervention: FC-assisted TUR without instillation
Number of subjects: 525
Study 25723356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry extract and juice beverage (CEJB)
Number of subjects: 59
Study 25723356 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie cranberry juice cocktail (LCJC)
Number of subjects: 59
Study 25723356 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 59
Study 23826245 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal LV pacing configurations
Number of subjects: 16
Study 23826245 — intervention group
Group type: COMPARATOR
Intervention: Worst LV pacing configurations
Number of subjects: 16
Study 23826245 — intervention group
Group type: COMPARATOR
Intervention: Default distal LV pacing configurations
Number of subjects: 16
Study 23826245 — intervention group
Group type: COMPARATOR
Intervention: Comparison of optimal vs worst LV pacing configurations
Number of subjects: 16
Study 20736244 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB blood flow based on cardiac index (CI)
Number of subjects: 22
Study 20736244 — intervention group
Group type: COMPARATOR
Intervention: CPB blood flow based on body surface area (BSA)
Number of subjects: 22
Study 19538625 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention
Number of subjects: 219
Study 19538625 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating control group
Number of subjects: 219
Study 16432463 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of at least one R241 allele
Number of subjects: 0
Study 16432463 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble ICAM-1 levels above 10 ng/ml
Number of subjects: 0
Study 16432463 — intervention group
Group type: EXPERIMENTAL
Intervention: K469E polymorphism
Number of subjects: 0
Study 14744737 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional care
Number of subjects: 353
Study 14744737 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care only
Number of subjects: 353
Study 14744737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nothing
Number of subjects: 353
Study 14744737 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care
Number of subjects: 353
Study 11606667 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (24-32 mg/day)
Number of subjects: 386
Study 11606667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 9777760 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide resurfacing laser 1
Number of subjects: 16
Study 9777760 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide resurfacing laser 2
Number of subjects: 16
Study 9777760 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide resurfacing laser 3
Number of subjects: 16
Study 9777760 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study 8170654 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam brush saturated with chlorhexidine
Number of subjects: 0
Study 8170654 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush
Number of subjects: 0
Study 3678263 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg day-1)
Number of subjects: 62
Study 3678263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 3678263 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 62
Study 29739665 — intervention group
Group type: EXPERIMENTAL
Intervention: Large diameter lenses
Number of subjects: 25
Study 27891180 — intervention group
Group type: EXPERIMENTAL
Intervention: Forefoot cushioning (FC)
Number of subjects: 23
Study 27891180 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 23
Study 27891180 — intervention group
Group type: EXPERIMENTAL
Intervention: Metatarsal pad (MP)
Number of subjects: 23
Study 24231437 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Specific Instrumentation (PSI)
Number of subjects: 36
Study 24231437 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical instruments (STD)
Number of subjects: 36
Study 24520744 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal vein patch modification
Number of subjects: 60
Study 24520744 — intervention group
Group type: COMPARATOR
Intervention: Control group (other forms of modification)
Number of subjects: 60
Study 21160018 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with autologous platelet-rich fibrin matrix (PRFM)
Number of subjects: 88
Study 21160018 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic rotator cuff repair without augmentation
Number of subjects: 88
Study 19069461 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid (600 mg/day)
Number of subjects: 0
Study 19069461 — intervention group
Group type: EXPERIMENTAL
Intervention: mexidol (300 mg/day)
Number of subjects: 0
Study 16596054 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hyperthyroidism (group A)
Number of subjects: 45
Study 16596054 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hyperthyroidism on medical therapy (group B)
Number of subjects: 45
Study 16596054 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 45
Study 14555901 — intervention group
Group type: COMPARATOR
Intervention: ACUVUE 2
Number of subjects: 20
Study 14555901 — intervention group
Group type: EXPERIMENTAL
Intervention: PureVision
Number of subjects: 20
Study 10961056 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) in patients without URI (M NO URI)
Number of subjects: 400
Study 10961056 — intervention group
Group type: COMPARATOR
Intervention: Uncuffed Orotracheal Tube (T) in patients without URI (T NO URI)
Number of subjects: 400
Study 10961056 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) in patients with URI (M URI)
Number of subjects: 400
Study 10961056 — intervention group
Group type: COMPARATOR
Intervention: Uncuffed Orotracheal Tube (T) in patients with URI (T URI)
Number of subjects: 400
Study 8648215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sialylated gonococci
Number of subjects: 11
Study 8648215 — intervention group
Group type: COMPARATOR
Intervention: Unsialylated gonococci
Number of subjects: 11
Study 1442643 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal hypnosis with different treatment strategies (groups one and two)
Number of subjects: 32
Study 1442643 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (group three, no hypnosis)
Number of subjects: 32
Study 3512396 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (0.1 microgram/kg/min)
Number of subjects: 6
Study 3512396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31751012 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily)
Number of subjects: 556
Study 31751012 — intervention group
Group type: COMPARATOR
Intervention: Comparator EGFR-TKIs (gefitinib at 250 mg once daily or erlotinib at 150 mg once daily)
Number of subjects: 556
Study 31751012 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 556
Study 31751012 — intervention group
Group type: COMPARATOR
Intervention: Comparator EGFR-TKIs
Number of subjects: 556
Study 29576358 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS (400 mg PS & 400 mg PA per day)
Number of subjects: 40
Study 27578478 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 μg
Number of subjects: 3474
Study 27578478 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 μg
Number of subjects: 3474
Study 27578478 — intervention group
Group type: COMPARATOR
Intervention: Placebo 5 μg
Number of subjects: 3474
Study 27578478 — intervention group
Group type: COMPARATOR
Intervention: Placebo 2.5 μg
Number of subjects: 3474
Study 24918372 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 281
Study 24918372 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal supplemental oxygen
Number of subjects: 281